Core Insights - Johnson & Johnson's MedTech segment achieved a 5.4% year-over-year growth in operational sales, reaching approximately $33.8 billion in 2025 [1] - The Innovative Medicine segment also saw growth, with operational sales increasing by 5.3% to about $60.4 billion [2] - The company anticipates overall worldwide operational sales growth of 5.7% to 6.2%, potentially exceeding the $100 billion milestone [6] MedTech Segment Performance - The growth in the MedTech segment was primarily driven by electrophysiology products, Abiomed in the Cardiovascular area, and wound closure products in General Surgery [4] - Abiomed reported an operational growth of 18% in Q4, while Shockwave achieved a 23% growth [4] - Johnson & Johnson completed the acquisition of Shockwave in May 2024, which is expected to enhance the technology's annual sales to at least $1 billion [5] Future Outlook - Both the Shockwave and Carvykti platforms surpassed $1 billion in annual sales for the first time, increasing the total number of platforms generating at least that much revenue to 28 [6] - The company is positioned to become the only healthcare company generating over $100 billion in revenue, supported by its diverse strengths in both Innovative Medicine and MedTech [7]